{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T02:26:52Z","timestamp":1794709612997,"version":"4.9.1"},"reference-count":52,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T00:00:00Z","timestamp":1626998400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To study whether delivering definitive radiotherapy (RT) to sites of oligoprogression in metastatic renal cell carcinoma (mRCC) enabled deferral of systemic therapy (ST) changes without compromising disease control or survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>We identified patients with mRCC who received RT to three or fewer sites of extracranial progressive disease between 2014 and 2019 at a large tertiary cancer centre. Inclusion criteria were: (1) controlled disease for \u22653\u2009months before oligoprogression, (2) all oligoprogression sites treated with a biologically effective dose of \u2265100\u2009Gy, and (3) availability of follow\u2010up imaging. Time\u2010to\u2010event end\u2010points were calculated from the start of RT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 72 patients were identified (median follow\u2010up 22\u2009months, 95% confidence interval [CI] 19\u201332\u2009months), with oligoprogressive lesions in lung\/mediastinum (\n                      <jats:italic>n\u2009<\/jats:italic>\n                      =\u200935), spine (\n                      <jats:italic>n\u2009<\/jats:italic>\n                      =\u200930), and non\u2010spine bone (\n                      <jats:italic>n\u2009<\/jats:italic>\n                      =\u20095). The most common systemic therapies before oligoprogression were none (\n                      <jats:italic>n\u2009<\/jats:italic>\n                      =\u200933), tyrosine kinase inhibitor (\n                      <jats:italic>n\u2009<\/jats:italic>\n                      =\u200923), and immunotherapy (\n                      <jats:italic>n\u2009<\/jats:italic>\n                      =\u200913). At 1\u2009year, the local control rate was 96% (95% CI 87\u201399%); progression\u2010free survival (PFS), 52% (95% CI 40\u201363%); and overall survival, 91% (95% CI 82\u201396%). At oligoprogression, ST was escalated (\n                      <jats:italic>n\u2009<\/jats:italic>\n                      =\u200916), maintained (\n                      <jats:italic>n\u2009<\/jats:italic>\n                      =\u200949), or discontinued (\n                      <jats:italic>n\u2009<\/jats:italic>\n                      =\u20097), with corresponding median (95% CI) PFS intervals of 19.7\u2009(8.2\u201327.2)\u2009months, 10.1\u2009(6.9\u201313.2)\u2009months, and 9.8\u2009(2.4\u201328.9)\u2009months, respectively. Of the 49 patients maintained on the same ST at oligoprogression, 21 did not subsequently have ST escalation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients with oligoprogressive mRCC treated with RT had comparable PFS regardless of ST strategy, suggesting that RT may be a viable approach for delaying ST escalation. Randomised controlled trials comparing treatment of oligoprogression with RT vs ST alone are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bju.15541","type":"journal-article","created":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T15:09:03Z","timestamp":1625584143000},"page":"610-620","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation"],"prefix":"10.1111","volume":"129","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3468-3359","authenticated-orcid":false,"given":"Brian","family":"De","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology The University of Texas MD Anderson Cancer Center  Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aradhana M.","family":"Venkatesan","sequence":"additional","affiliation":[{"name":"Department of Abdominal Imaging Division of Diagnostic Imaging The University of Texas MD Anderson Cancer Center  Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6505-8308","authenticated-orcid":false,"given":"Pavlos","family":"Msaouel","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology Division of Cancer Medicine The University of Texas MD Anderson Cancer Center  Houston TX USA"},{"name":"Department of Translational Molecular Pathology Division of Pathology and Laboratory Medicine The University of Texas MD Anderson Cancer Center  Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amol J.","family":"Ghia","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology The University of Texas MD Anderson Cancer Center  Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology The University of Texas MD Anderson Cancer Center  Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra N.","family":"Yeboa","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology The University of Texas MD Anderson Cancer Center  Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quynh\u2010Nhu","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology The University of Texas MD Anderson Cancer Center  Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Bishop","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology The University of Texas MD Anderson Cancer Center  Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Jonasch","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology Division of Cancer Medicine The University of Texas MD Anderson Cancer Center  Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amishi Y.","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology Division of Cancer Medicine The University of Texas MD Anderson Cancer Center  Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew T.","family":"Campbell","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology Division of Cancer Medicine The University of Texas MD Anderson Cancer Center  Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology Division of Cancer Medicine The University of Texas MD Anderson Cancer Center  Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amado J.","family":"Zurita\u2010Saavedra","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology Division of Cancer Medicine The University of Texas MD Anderson Cancer Center  Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A.","family":"Karam","sequence":"additional","affiliation":[{"name":"Department of Translational Molecular Pathology Division of Pathology and Laboratory Medicine The University of Texas MD Anderson Cancer Center  Houston TX USA"},{"name":"Department of Urology Division of Surgery The University of Texas MD Anderson Cancer Center  Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3450-8809","authenticated-orcid":false,"given":"Christopher G.","family":"Wood","sequence":"additional","affiliation":[{"name":"Department of Urology Division of Surgery The University of Texas MD Anderson Cancer Center  Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1638-1445","authenticated-orcid":false,"given":"Surena F.","family":"Matin","sequence":"additional","affiliation":[{"name":"Department of Urology Division of Surgery The University of Texas MD Anderson Cancer Center  Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar M.","family":"Tannir","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology Division of Cancer Medicine The University of Texas MD Anderson Cancer Center  Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5915-1327","authenticated-orcid":false,"given":"Chad","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology The University of Texas MD Anderson Cancer Center  Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,7,23]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.06.049"},{"key":"e_1_2_10_4_1","unstructured":"National Comprehensive Cancer Network (NCCN).NCCN Clinical Practice Guidelines in Oncology. Kidney Cancer 2020. Available at:https:\/\/www.nccn.org\/guidelines\/category_1. Accessed July 2021"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2020.100166"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2018.07.018"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1113205"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2011.44"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2012.00049"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-018-0746-y"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2017.08.010"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.04.008"},{"key":"e_1_2_10_13_1","unstructured":"The World Medical Association: Ferney\u2010Voltaire F.Declaration of Helsinki: Ethical principles for medical research involving human subjects 2013. Available at:https:\/\/www.wma.net\/policies\u2010post\/wma\u2010declaration\u2010of\u2010helsinki\u2010ethical\u2010principles\u2010for\u2010medical\u2010research\u2010involving\u2010human\u2010subjects\/. Accessed July 2021"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19971215)80:12 <2519::AID-CNCR26>3.0.CO;2-E"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70559-4"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.4809"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1586\/era.10.195"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1262"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.6_suppl.654"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0813-8"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30196-6"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.06.1957"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20160251"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.5065"},{"key":"e_1_2_10_26_1","unstructured":"ClinicalTrials.gov Sunnybrook Health Sciences Centre Pfizer.Stereotactic Radiotherapy for Metastatic Kidney Cancer Being Treated With Sunitinib 2014. Available at:https:\/\/ClinicalTrials.gov\/show\/NCT02019576. Accessed July 2021"},{"key":"e_1_2_10_27_1","unstructured":"ClinicalTrials.gov University of Texas Southwestern Medical Center.SAbR For Oligo\u2010Progressive Renal Cell Cancer 2018. Available at:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03696277. Accessed July 2021"},{"key":"e_1_2_10_28_1","unstructured":"ClinicalTrials.gov Centre Francois Baclesse National Cancer Institute France GETUG.Study Assessing Stereotactic Radiotherapy in Therapeutic Strategy of Oligoprogressive Renal Cell Carcinoma Metastases (GETUG\u2010StORM\u201001) 2020. Available at:https:\/\/ClinicalTrials.gov\/show\/NCT04299646. Accessed July 2021"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2019.05.015"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2020.100216"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0508"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2018.09.015"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy275"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2013.11.010"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2019.08.012"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-019-02717-7"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.06.011"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2019-001115"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00961"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11101559"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2019.08.018"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2020.07.008"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2019.04.006"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-020-00936-5"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000333"},{"key":"e_1_2_10_46_1","unstructured":"ClinicalTrials.gov Lawson Health Research Institute.Stereotactic Radiotherapy for Oligo\u2010Progressive Metastatic Cancer (The STOP Trial) 2016. Available at:https:\/\/ClinicalTrials.gov\/show\/NCT02756793. Accessed July 2021"},{"key":"e_1_2_10_47_1","unstructured":"ClinicalTrials.gov Memorial Sloan Kettering Cancer Center.Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung 2019. Available at:https:\/\/ClinicalTrials.gov\/show\/NCT03808662. Accessed July 2021"},{"key":"e_1_2_10_48_1","unstructured":"ClinicalTrials.gov Institute of Cancer Research UK.Stereotactic Body Radiotherapy for the Treatment of OPD (HALT) 2017. Available at:https:\/\/ClinicalTrials.gov\/show\/NCT03256981. Accessed July 2021"},{"key":"e_1_2_10_49_1","unstructured":"ClinicalTrials.gov University of Michigan Rogel Cancer Center.FOcal Radiation for Oligometastatic Castration\u2010rEsistant Prostate Cancer (FORCE) 2018. Available at:https:\/\/ClinicalTrials.gov\/show\/NCT03556904. Accessed July 2021"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.566070"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajur.2016.08.006"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr362"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.03.057"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.15541","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bju.15541","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.15541","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T16:11:46Z","timestamp":1761754306000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.15541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,23]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1111\/bju.15541"],"URL":"https:\/\/doi.org\/10.1111\/bju.15541","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,23]]},"assertion":[{"value":"2021-02-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}